Kairos Pharma Sets Virtual Annual Meeting, Discloses Going Concern Notice

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on oncology therapeutics, has announced that its annual meeting of shareholders will be held virtually at 9 a.m. PDT on June 29, 2026. Meeting materials will be mailed following finalization and filing with the Securities and Exchange Commission. The company also disclosed that its 2025 annual report includes an audit report containing a going concern explanatory paragraph from its independent registered public accounting firm, as required under Section 610(b) of the NYSE American Company Guide. The disclosure does not reflect any change or amendment to previously filed financial statements.

The going concern notice indicates substantial doubt about the company’s ability to continue as a going concern, a critical disclosure for investors. This typically arises when a company faces recurring losses, negative cash flows, or other financial challenges that may impair its ability to meet obligations. For Kairos Pharma, which has yet to generate revenue from product sales and relies on funding to support its research and development, this notice highlights the financial risks inherent in drug development.

Based in Los Angeles, California, Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.

The virtual annual meeting provides shareholders an opportunity to vote on corporate matters and hear updates from management. The going concern disclosure, while not altering past financial statements, serves as a red flag for investors monitoring the company’s liquidity and ability to fund its pipeline. The company’s ability to secure additional financing or partnerships will be crucial to advancing ENV-105 through clinical trials and toward potential commercialization.

For more details, the full press release is available at https://ibn.fm/sQ0pm. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.